Search results
Jump to navigation
Jump to search
Page title matches
- ...retic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J Nesiritide is considered adjunctive therapy for patients in severe heart failure, prin2 KB (299 words) - 21:01, 2 March 2010
- 121 bytes (15 words) - 20:41, 2 March 2010
- 281 bytes (37 words) - 20:45, 2 March 2010
Page text matches
- #REDIRECT [[Nesiritide]]24 bytes (2 words) - 20:38, 2 March 2010
- ...retic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J Nesiritide is considered adjunctive therapy for patients in severe heart failure, prin2 KB (299 words) - 21:01, 2 March 2010
- {{r|Nesiritide}}279 bytes (30 words) - 00:30, 3 March 2010
- ...12124404&promo=ONFLNS19 |issn=}}</ref> A recombinant DNA version of BNP, [[nesiritide]] (trade name Natrecor), is also given as a treatment for heart failure. ==Treatment with nesiritide==11 KB (1,470 words) - 14:35, 18 March 2024
- ...retic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J13 KB (1,669 words) - 07:45, 9 June 2014
- ...retic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J73 KB (10,150 words) - 21:46, 20 August 2014